SmartBrief > Health Care > AAP SmartBrief > Related Stories

FDA approves pediatric dose of Abbott's enzyme drug Creon

The FDA approved a 3,000-unit lipase capsule of Abbott Laboratories' Creon to treat exocrine pancreatic insufficiency in infants with cystic fibrosis. "This approval means that Creon will now be available in four dosing options, including both the lowest and highest dosage strengths available to patients in the United States, providing improved dosing titration options and flexibility into adulthood," said Eugene Sun, Abbott's vice president of global pharmaceutical development.

Share

This news summary appeared in AAP SmartBrief on 06/15/2011
Click here to view the full issue.


View the original article:
Wall Street Journal, The

Want to see more news summaries?
Sign up for AAP SmartBrief
AAP SmartBrief is a FREE, daily email newsletter that summarizes the day's top industry news from hundreds of sources. Each day, subscribers receive 8-10 headlines and news summaries like the one to the left
Sign up:
About SmartBrief
SmartBrief is the leading online publisher of targeted business news and information by industry. By combining technology and editorial expertise, SmartBrief filters thousands of sources daily to deliver the most relevant industry news in partnership with more than 180 trade associations, professional societies nonprofits and corporate entities